Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
2 Combination of eGFR and UACR Better Predicts CKD Progression
3 Alexander Spira, MD, PhD, Discusses Safety and Efficacy of Mobocertinib in EGFR ex20ins+ NSCLC Following Prior EGFR TKIs
4 More Precise NSCLC Treatment Selection Boosted by Using EGFR Mutation Structure and Function
5 Neoadjuvant Osimertinib Yields Promising Benefit in EGFR-Positive Non–Small Cell Lung Cancer
6 Clinical Outcomes of Patients Taking First-generation EGFR-TKIs May Predict the Benefits Afforded by Osimertinib in EGFR T790M-mutant NSCLC Patients
7 Future Treatments for EGFR-Positive NSCLC: Ask the Expert
8 Removing Race From eGFR Equations May Lead to Undertreatment in Cancer Patients
9 Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC
10 SqCLC Harboring EGFR p.E746_S752delinsV Mutation Patient | OTT
11 Pelcitoclax Plus Osimertinib Shows Promise in Patients With EGFR TKI–Resistant NSCLC
12 Cystatin C-based eGFR changes Black patients' CKD prevalence less than race-free equations
13 Mobocertinib Elicits Antitumor Activity in EGFR Exon 20 Insertion+ NSCLC After Disease Control With EGFR TKIs
14 Clinical Activity Observed With Mobocertinib for Advanced EGFR Exon 20 Insertion+ NSCLC With or Without Prior Immunotherapy
15 Measures of Kidney Function as CV Risk Factors in Older Adults
16 MD Anderson Study Further Supports Using Liquid Biopsy First to Gauge EGFR Mutations in Lung Cancer
17 Clinical Activity Shown With Mobocertinib in Advanced EGFR Exon 20 Insertion+ NSCLC, Regardless of Prior I/O
18 Investigators Initiate Treatment With ERAS-007 in Patients With EGFR-Positive NSCLC
19 Amivantamab shows efficacy on EGFR Exon20ins mutations in NSCLC
20 No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC
21 EGFR Mutation Heterogeneity
22 Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Ex | IJGM
23 Osimertinib in EGFR-mutated lung cancer | OTT
24 Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer
25 Clinical Pearls: EGFR Exon 20 Insertion+ NSCLC Treatment
26 Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
27 Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC
28 Testing for EGFR mutations and ALK rearrangements | OTT
29 Efficacy and prognosis of first-line EGFR-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with EGFR -mutated non-small-cell lung cancer
30 Latest data suggest commonly used CKD definition inflates burden of disease
31 Mobocertinib: A Treatment Option for EGFR and Exon 20 Insertions
32 Scientists discover new pathway that prevents bowel cancer treatment from working
33 Urate-Lowering Therapies for Hyperuricemia in CKD Not Renoprotective
34 COVID-19 long-haulers show elevated risks for kidney damage, including ESKD
35 'Golf Courtney's Way' to help end EGFR lung cancer – Hamilton County Reporter
36 Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5
37 Erasca Begins HERKULES-2 Trial of ERAS-007, Tagrisso in EGFR-mutated NSCLC
38 Molecular epidemiology and direct medical costs of EGFR | LCTT
39 EGFR-Targeted TKIs in NSCLC and Cost
40 Lower Post-Nephrectomy Kidney Function May Up ESKD Risk
41 Kidney test adjustment based on ethnicity cut from UK medical guidance
42 Place for EGFR Agents and Comparison of Costs
43 Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs
44 Indian patients with EGFR-positive advanced non-small cell lung cancer (NSCLC) to benefit with monotherapy d..
45 Chronic Kidney Disease May Be Overestimated in the Elderly
46 Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
47 CKD Associated With Worse Radical Cystectomy Outcomes
48 'Long COVID' Raises Kidney Damage Risk
49 Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
50 Kidney Disease No Barrier to Effient Benefit in ACS
51 Early Target Identification Will Help Maximize Osimertinib Treatment
52 Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation of Data for Poziotinib in First-Line NSCLC Patients with HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2021
53 LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
54 The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform
55 EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP)
56 Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report
57 Takeda scores a win for a rare type of lung cancer, gearing up for a showdown with J&J
58 Oncocyte Launches Prospective Registry to Drive DetermaRx Adoption, Improve Coverage
59 Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney Disease
60 Amgen rolls out data for KRAS inhibitor combo study in colorectal cancer, hoping to move on from ugly early results
61 Pathway Prevents Bowel Cancer Treatment From Working
62 Researchers discover new pathway that makes drugs less effective in bowel cancer patients
63 Roundtable Discussion: Osimertinib Is Chosen as Best Option for Frontline Therapy for EGFR+ NSCLC
64 Juntendo University research: Aromatherapy in medicine: Essential oils prove to be effective against skin cancer
65 Post-Acute Kidney Sequelae Studied in COVID-19 Survivors
66 Nuvectis Pharma Grows Precision Oncology Pipeline With University of Edinburgh's SRC/YES1 Inhibitor
67 'Lung cancer drug Leclaza to be used more broadly through various trials'
68 Scientists discover new pathway that prevents bowel cancer treatment from working
69 Roundtable Discussion: Camidge and Participants Review Possible Therapeutic Combinations and Monotherapy in NSCLC
70 PDUFA Date Extended for IgA Nephropathy Treatment Application
71 Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript
72 Dropping Race From eGFR Doubles Estimated Prevalence of CKD in Black Populations
73 Non-alcoholic Fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes
74 Flawed Racial Assumptions in eGFR Have Care Implications in CKD
75 US Kidney-Group Presidents Say 'Drop the eGFR Race Modifier'
76 Immune checkpoint inhibitors linked to rapid eGFR decline, development of kidney disease
77 Lung cancer causes: Is it genetic?
78 Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLC
79 Removing Race From eGFR Equations May Improve Care of Black Patients
80 Task Force Reviewing Race Modifier in eGFR Issues Interim Report
81 How the eGFR tool could be hurting Black patients
82 EGFR activation limits the response of liver cancer to lenvatinib
83 Decreased eGFR correlates with poorer outcomes after intracerebral hemorrhage
84 Study Examines Clinical Implications of Removing Race From eGFR in Chronic Kidney Disease
85 4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC
86 Targeted treatments for EGFR-positive lung cancer can improve outcomes
87 COVID-19-Associated Kidney Injuries Linked to Decreased eGFR
88 EGFR Mutation Lung Cancer: Symptoms, Diagnosis, and Treatment
89 EGFR mutation lung cancer: Definition, outlook, treatment, and more
90 Nonlinear eGFR decline more likely for African Caribbean adults with type 2 diabetes
91 Why eGFR-reporting change helps tackle kidney disease inequities
92 Novel therapy shows promise for lung cancer patients with rare EGFR mutation
93 Travere Therapeutics : Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
94 EGFR Mutation and Lung Cancer: Your FAQs
95 TRAVERE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
96 FDA Approves Rybrevant for Advanced NSCLC With EGFR Mutations
97 In Search of a Better Equation — Performance and Equity in Estimates of Kidney Function | NEJM
98 Amivantamab Paves a New Treatment Path for Patients With EGFR Exon 20–Mutant NSCLC
99 Could Nixing Race-Adjustments for eGFR Harm Black Cancer Patients?
100 Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC